Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings
08:00am, Wednesday, 29'th Jan 2025
Biotech stocks will need to brace for political "games" Wednesday as the Senate meets to potentially confirm RFK Jr. to lead HHS. The post The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senat
Diatech Pharmacogenetics Expands Collaboration with Merck to Enhance Patient Access to Personalized Medicine in the Middle East and Africa
06:00am, Wednesday, 29'th Jan 2025
JESI, Italy--(BUSINESS WIRE)--Diatech Pharmacogenetics announced an expansion of its collaboration with Merck Serono Middle East Ltd., affiliates of Merck KGaA (“Merck”). The collaboration aims to
Merck Announces Second-Quarter 2025 Dividend and $10 Billion Share Repurchase Authorization
01:28pm, Tuesday, 28'th Jan 2025
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Second-Quarter 2025 Dividend and $10 Billion Share Repurchase Authorization.
MRK's sNDA for Welireg in Rare Tumors Gets FDA's Priority Tag
01:10pm, Tuesday, 28'th Jan 2025
The FDA accepts and grants priority review to Merck's sNDA for Welireg to treat advanced pheochromocytoma and paraganglioma. A decision is due on May 26, 2025.
Merck (MRK) Earnings Expected to Grow: Should You Buy?
11:05am, Tuesday, 28'th Jan 2025
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck Q4 Earnings Coming Up: Buy, Hold or Sell MRK Stock Now?
10:26am, Tuesday, 28'th Jan 2025
When Merck reports fourth-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.
MRK Reports Mixed Keytruda Combo Study Data in Gastroesophageal Cancer
11:45am, Monday, 27'th Jan 2025
The LEAP-015 study is evaluating Merck's Keytruda and Eisai's Lenvima plus chemotherapy in certain types of gastroesophageal adenocarcinoma.
Why This Beaten-Down Stock Is a Buy in 2025 and Beyond
08:45am, Monday, 27'th Jan 2025
Last year wasn't a good one for Merck (MRK -1.12%), one of the largest pharmaceutical companies in the world. The healthcare giant is dealing with the fast-approaching patent cliff for its most import
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Accepts for Priority Review Merck's Application for WELIREG for Treatment of Advanced PPGL.
These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024
06:17am, Saturday, 25'th Jan 2025
The Dow Jones Industrial Average (DJIA) is a group of 30 U.S. industry leaders. It's often looked at as a proxy for the market, since its components' performance is indicative of what's happening in t
Merck and Eisai's cancer drugs fail to improve overall survival in late-stage trial
07:01am, Friday, 24'th Jan 2025
Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve overall survival in patients with a type of esophageal cancer in a late-stage tri
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial.
4 Mega-Cap High-Yield Dividend Giants Look Like Huge 2025 Winners
06:18am, Thursday, 23'rd Jan 2025
Investors love dividend stocks, especially the high-yield mega-cap variety, because they offer a significant income stream and have massive total return potential.
Kennedy would keep legal fees from Merck cases if confirmed
06:44pm, Wednesday, 22'nd Jan 2025
Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President Donald Trump's secretary of the U.S. Department of Health and Human Service
Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know
06:56pm, Tuesday, 21'st Jan 2025
In the latest trading session, Merck (MRK) closed at $96.24, marking a -1.72% move from the previous day.
